Understanding heart function and biomarkers in aortic stenosis patients
Official title: The Role of Cardiac Mechanics, Circulating Biomarkers and Frailty in Aortic Stenosis in Predicting Outcomes After Aortic Valve Intervention.
Run by Montreal Heart Institute · NCT02856620 · Data updated 2026-11-12
This study is trying to see how heart function, certain blood markers, and overall health can help predict how well patients with aortic stenosis do after getting their heart valve replaced.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 450 (estimated) |
| Sponsor | Montreal Heart Institute Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | July 2016 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | November 22, 2024 |
| Trial ID | NCT02856620 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with moderate to severe aortic stenosis or heart failure with preserved ejection fraction.
✕Probably not a fit
Patients who have previously undergone aortic valve replacement or have significant mitral valve disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the role of cardiac mechanics, biomarkers, and frailty in predicting outcomes for patients with aortic stenosis after undergoing aortic valve replacement. It consists of two parts: the first part analyzes existing data to identify phenotypes and biomarkers that indicate symptom severity in patients with aortic stenosis and heart failure with preserved ejection fraction. The second part is a prospective cohort study aimed at developing a functional capacity score that incorporates various clinical and structural parameters to enhance risk stratification and patient selection for aortic valve interventions.
Why it matters
Potential benefit: If successful, this study could lead to improved patient selection and outcomes for those undergoing aortic valve replacement.
How similar studies have gone: Other studies have shown promise in using biomarkers and cardiac mechanics for patient stratification, but this specific approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Part I - Patients part of the TOPCAT cohort from Americas fulfilling inclusion criteria of Part II-Group 3 (see below) and/or patients enrolled in the Part II study Part II - Segment A and B Age ≥ 18 years old AS classified according to aortic valve area measured by Doppler echocardiography Group 1: Moderate AS (1.0-1.5cm2) Group 2: Severe AS (1cm2) Group 3: HF with preserved left ventricular ejection fraction (LVEF ≥45%) without significant AS Part II - Segment C (Control Group) Age ≥ 18 years old Healthy subject taking into account exclusions parameters at the time of screening Able to sign the consent form Exclusion Criteria: Part I and II - Segment A and B Prior AVR either by surgery or trans-aortic valve implantation; Severe mitral valve disease or aortic regurgitation; LVEF \< 45% Myocardial infarction within the previous 3 months; Angina limiting the 6MWTD and thought to be the result of severe coronary artery disease; Cerebrovascular transient ischemic attack or stroke within the previous 6 months; Known active infection or cancer; renal insufficiency (glomerular filtration rate \<30 mL/min/1.73m2) or end-stage renal disease; Significant anemia (haemoglobin \<90 g/L) or thrombocytopenia (platelet count \<50), history of bleeding diathesis or coagulopathy; Life expectancy \<12 months due to non-cardiac co-morbid conditions; Chronic obstructive pulmonary disease with Global initiative for chronic obstructive lung disease (GOLD) stages 3-4; musculoskeletal disease limiting the ability to perform the 6MWTD. Part II - Segment C (Control Group) History of cardiovascular disease Risk factors associated with cardiovascular (treated diabetes, hypertension, body mass index \>30kg/m2) Pregnancy or breastfeeding All other cause from Segment A and B
Where it's running
-
Montreal Heart Institute
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Christine Henri, MD — Montreal Heart Institute
- Study coordinator: Helene Brown, RN. B.Sc.
- Email: helene.brown@icm-mhi.org
- Phone: 514-376-3330
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Monitoring progression of chronic cardiovascular conditions
This project will collect wearable physiologic data from adults with cardiovascular conditions to see how their heart disease changes over time.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Investigating RNA profiles in heart failure and aortic stenosis
This study is trying to see how certain RNA molecules in the blood and heart tissue of people with heart failure and aortic stenosis might help us understand their heart problems better and identify new ways to diagnose them.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.